The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
Official Title: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Study ID: NCT00649207
Brief Summary: This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.
Detailed Description: This is a Phase 1, multicenter, dose-escalation study evaluating the safety, tolerability and pharmacokinetics of the PARP inhibitor ABT-888 in combination with conventional whole brain radiation therapy (WBRT) in the treatment of subjects with solid tumors metastatic to the brain.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Site Reference ID/Investigator# 8334, Atlanta, Georgia, United States
Site Reference ID/Investigator# 52462, Chicago, Illinois, United States
Site Reference ID/Investigator# 24483, Kansas City, Kansas, United States
Site Reference ID/Investigator# 7180, Baltimore, Maryland, United States
Site Reference ID/Investigator# 19021, Detroit, Michigan, United States
Site Reference ID/Investigator# 6344, Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 6653, Madison, Wisconsin, United States
Site Reference ID/Investigator# 18542, Toronto, , Canada
Site Reference ID/Investigator# 46322, Ponce, , Puerto Rico
Name: Shepherd L Stacie, MD
Affiliation: AbbVie
Role: STUDY_DIRECTOR